# Overcoming Diagnostic Challenges: A Rare Presentation of Primary Hemophagocytic Lymphohistiocytosis (HLH) in a Young Female and the Importance of Timely Recognition

**Authors:** Karthiga Selvaratnam, MSM Nusair, Pakkiyaretnam Mayurathan

PMC · DOI: 10.7759/cureus.60242 · Cureus · 2024-05-13

## TL;DR

This paper presents a rare case of a young adult diagnosed with a severe immune disorder and highlights the importance of early detection and treatment for better outcomes.

## Contribution

The paper contributes a rare case of primary HLH in an adult and emphasizes the value of timely diagnosis and treatment.

## Key findings

- A 26-year-old female was successfully treated for primary HLH following the HLH-2004 protocol.
- Early diagnosis and adherence to treatment protocols improved the patient's prognosis and led to recovery.
- The case underscores the importance of recognizing HLH in adults, which is typically seen in children.

## Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a severe life-threatening hematological disorder characterized by the dysregulation of the immune system and a hyperinflammatory response. Prompt treatment is crucial to prevent fatality. Although primarily affecting infants, HLH can also occur in children and adults. It is classified as primary and secondary, with primary HLH being genetic and predominantly affecting children. Secondary HLH is triggered by infections, malignancy, metabolic disorders, and rheumatological conditions. Diagnosis is based on the HLH-2004 criteria, considering clinical and laboratory parameters. Early diagnosis and treatment improve prognosis. Treatment follows the HLH-94 and HLH-2004 protocol and consists of eight weeks of induction therapy with cyclosporine, corticosteroids, and etoposide. This case describes a 26-year-old female diagnosed with HLH and successfully treated according to the protocol. The patient exhibited improvement and was discharged, demonstrating the importance of early diagnosis and appropriate management in adult HLH cases.

## Linked entities

- **Chemicals:** cyclosporine (PubChem CID 5284373), etoposide (PubChem CID 36462)
- **Diseases:** Hemophagocytic lymphohistiocytosis (MONDO:0015540), HLH (MONDO:0015540)

## Full-text entities

- **Diseases:** malignancy (MESH:D009369), metabolic disorders (MESH:D008659), hematological disorder (MESH:D006402), rheumatological conditions (MESH:D020763), HLH (MESH:D051359), infections (MESH:D007239)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11169998/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11169998/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC11169998/full.md

---
Source: https://tomesphere.com/paper/PMC11169998